Drugs / TCR-T cells targeting MAGE-A4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07467122 | Mar 2026 → Dec 2029 expected | sarcoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-T cells targeting MAGE-A4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07467122 ↗ |
| Modality | Cell therapy | “engineering autologous T cells with a high-affinity TCR specific for MAGE-A4” NCT07467122 ↗ |
| Target | MAGEA4 | “TCR-T cells targeting MAGE-A4” NCT07467122 ↗ |